Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 788

1. 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1) Journal of Investigative Dermatology · 2019 · 5 citations
2. Under Development JAK Inhibitors for Dermatologic Diseases Mediterranean Journal of Rheumatology · 2020 · 14 citations
3. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature Journal of Dermatological Treatment · 2016 · 40 citations
4. Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway Indian Dermatology Online Journal · 2023
5. Emerging Topical and Systemic JAK Inhibitors in Dermatology Frontiers in Immunology · 2019 · 277 citations
6. JAK inhibitors in dermatology: The promise of a new drug class Journal of the American Academy of Dermatology · 2017 · 355 citations
7. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021 · 40 citations
8. 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects Journal of Investigative Dermatology · 2023
9. 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata 2019
10. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream Pharmaceutics · 2021 · 24 citations

Community

— no results